(Go: >> BACK << -|- >> HOME <<)
Jump to content

"ଏନକୋରାଫେନିବ" ପୃଷ୍ଠାର ସଂସ୍କରଣ‌ଗୁଡ଼ିକ ମଧ୍ୟରେ ତଫାତ

ଉଇକିପିଡ଼ିଆ‌ରୁ
Browse history interactively
Content deleted Content added
ଭିଜୁଆଲWikitext
Created by translating the page "User:Mr. Ibrahem/Encorafenib"
 
Fix references, Expend infobox mdwiki.toolforge.org.
 
(ଆଉ ଜଣେ ବ୍ୟବହାରକାରୀଙ୍କ ଦ୍ୱାରା ହୋଇଥିବା ମଝି ସଂସ୍କରଣଟିଏ ଦେଖା ଯାଉନାହିଁ)
୧ କ ଧାଡ଼ି: ୧ କ ଧାଡ଼ି:
{{ଛୋଟ|Encorafenib}}
{{Infobox drug
{{Infobox drug
| drug_name =
| drug_name =
| type = <!-- empty -->
| type = <!-- empty -->
| IUPAC_name = Methyl [(2S)-1-<nowiki/>{[4-(3-<nowiki/>{5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl}-1-isopropyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino}-2-propanyl]carbamate
| IUPAC_name = Methyl [(2S)-1-<nowiki/>{[4-(3-<nowiki/>{5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl}-1-isopropyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino}-2-propanyl]carbamate


<!-- External links -->| image = LGX818 structure.svg
<!-- External links -->
| image = LGX818 structure.svg
| width = 240px
| width = 240px
| alt =
| alt =
| caption = <!-- Names -->
| caption = <!-- Names -->
| pronounce =
| pronounce =
| tradename = Braftovi
| tradename = Braftovi
| Drugs.com = {{drugs.com|monograph|encorafenib}}
| Drugs.com = {{drugs.com|monograph|encorafenib}}
| MedlinePlus = a618040
| MedlinePlus = a618040




<!-- Clinical data -->| licence_EU = <!-- EMA uses INN (or special INN_EMA) -->
<!-- Clinical data -->
| licence_EU = <!-- EMA uses INN (or special INN_EMA) -->
| licence_US = <!-- FDA may use generic or brand name (generic name preferred) -->
| licence_US = <!-- FDA may use generic or brand name (generic name preferred) -->


<!-- Pharmacokinetic data -->| DailyMedID = Encorafenib
<!-- Pharmacokinetic data -->
| DailyMedID = Encorafenib
| pregnancy_AU = <!-- A/B1/B2/B3/C/D/X -->
| pregnancy_AU = <!-- A/B1/B2/B3/C/D/X -->
| pregnancy_AU_comment =
| pregnancy_AU_comment=
| pregnancy_US = <!-- A / B / C / D / X / N -->
| pregnancy_US = <!-- A / B / C / D / X / N -->
| pregnancy_US_comment =
| pregnancy_US_comment=
| pregnancy_category =
| pregnancy_category=
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment =
| legal_AU_comment=
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment =
| legal_CA_comment=
| legal_DE = <!-- Anlage I, II, III or Unscheduled-->
| legal_DE = <!-- Anlage I, II, III or Unscheduled-->
| legal_DE_comment =
| legal_DE_comment=
| legal_EU = Rx-only
| legal_EU = Rx-only
| legal_EU_comment =
| legal_EU_comment=
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment =
| legal_NZ_comment=
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment =
| legal_UK_comment=
| legal_US = Rx-only
| legal_US = Rx-only
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_US_comment =
| legal_US_comment=
| legal_UN_comment =
| legal_UN_comment=
| legal_status = <!--For countries not listed above-->
| legal_status = <!--For countries not listed above-->
| dependency_liability =
| dependency_liability=
| addiction_liability =
| addiction_liability=
| routes_of_administration = [[Oral administration|By mouth]]
| routes_of_administration= [[Oral administration|By mouth]]
| bioavailability =
| bioavailability =
| protein_bound =
| protein_bound =
| metabolism =
| metabolism =
| metabolites =
| metabolites =
| onset =
| onset =
| elimination_half-life =
| elimination_half-life=
| duration_of_action =
| duration_of_action=
| excretion = <!-- Chemical and physical data -->
| excretion = <!-- Chemical and physical data -->
| synonyms = LGX818
| synonyms = LGX818
| chemical_formula =
| chemical_formula=
| C = 22
| C = 22
| Cl = 1
| Cl = 1
| F = 1
| F = 1
| H = 27
| H = 27
୬୦ କ ଧାଡ଼ି: ୬୪ କ ଧାଡ଼ି:
| O = 4
| O = 4
| S = 1
| S = 1
| SMILES = C[C@@H](CNc1nccc(n1)c2cn(nc2c3cc(cc(c3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC
| SMILES = C[C@@H](CNc1nccc(n1)c2cn(nc2c3cc(cc(c3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC
| StdInChI = 1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1
| StdInChI = 1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1
| StdInChI_comment =
| StdInChI_comment=
| StdInChIKey = CMJCXYNUCSMDBY-ZDUSSCGKSA-N
| StdInChIKey = CMJCXYNUCSMDBY-ZDUSSCGKSA-N
| density =
| density =
| density_notes =
| density_notes =
| melting_point =
| melting_point =
| melting_high =
| melting_high =
| melting_notes =
| melting_notes =
| boiling_point =
| boiling_point =
| boiling_notes =
| boiling_notes =
| solubility =
| solubility =
| specific_rotation =
| specific_rotation=
}}
}}


'''ଏନକୋରାଫେନିବ ([[ଇଂରାଜୀ ଭାଷା|ଇଂରାଜୀ ଭାଷାରେ]] Encorafenib), ବ୍ରାଫ୍ଟୋଭି''' ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି [[ମେଲାନୋମା]] ଏବଂ [[ବୃହଦନ୍ତ୍ର-ମଳାଶୟ କର୍କଟ|ବୃହଦନ୍ତ୍ର ମଳାଶୟ କର୍କଟ ରୋଗର]] ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ଏକ ଔଷଧ ।<ref name="PI2021">{{Cite web |title=DailyMed - BRAFTOVI- encorafenib capsule |url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c |url-status=live |archive-url=https://web.archive.org/web/20210421103420/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c |archive-date=21 April 2021 |access-date=15 December 2021 |website=dailymed.nlm.nih.gov}}</ref> ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ବ୍ୟବହୃତ ହୁଏ ଯେତେବେଳେ ଅସ୍ତ୍ରୋପଚାର ଦ୍ୱାରା ବିଆରଏଏଫ ଭି୬୦୦ଇ (BRAF V600E) କିମ୍ବା ଭି୬୦୦କେ (V600K) ମ୍ୟୁଟେସନ୍-ପଜିଟିଭ୍ ରୋଗ ଅପସାରଣ କରାଯାଇପାରିବ ନାହିଁ ।<ref name="PI2021">{{cite web |title=DailyMed - BRAFTOVI- encorafenib capsule |url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c |website=dailymed.nlm.nih.gov |accessdate=15 December 2021 |archive-date=21 April 2021 |archive-url=https://web.archive.org/web/20210421103420/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c |url-status=live }}</ref> ଏହା ପାଟିରେ ଦିଆଯାଏ ।<ref name="AHFS2021">{{Cite web|title=Encorafenib Monograph for Professionals |url=https://www.drugs.com/monograph/encorafenib.html |website=Drugs.com |language=en |archive-date=20 July 2021 |archive-url=https://web.archive.org/web/20210720091715/https://www.drugs.com/monograph/encorafenib.html |url-status=live |access-date=15 December 2021}}</ref>
'''ଏନକୋରାଫେନିବ ([[ଇଂରାଜୀ ଭାଷା|ଇଂରାଜୀ ଭାଷାରେ]] Encorafenib), ବ୍ରାଫ୍ଟୋଭି''' ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି [[ମେଲାନୋମା]] ଏବଂ [[ବୃହଦନ୍ତ୍ର-ମଳାଶୟ କର୍କଟ|ବୃହଦନ୍ତ୍ର ମଳାଶୟ କର୍କଟ ରୋଗର]] ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ଏକ ଔଷଧ ।<ref name="PI2021">{{Cite web |title=DailyMed - BRAFTOVI- encorafenib capsule |url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c |url-status=live |archive-url=https://web.archive.org/web/20210421103420/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c |archive-date=21 April 2021 |access-date=15 December 2021 |website=dailymed.nlm.nih.gov}}</ref> ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ବ୍ୟବହୃତ ହୁଏ ଯେତେବେଳେ ଅସ୍ତ୍ରୋପଚାର ଦ୍ୱାରା ବିଆରଏଏଫ ଭି୬୦୦ଇ (BRAF V600E) କିମ୍ବା ଭି୬୦୦କେ (V600K) ମ୍ୟୁଟେସନ୍-ପଜିଟିଭ୍ ରୋଗ ଅପସାରଣ କରାଯାଇପାରିବ ନାହିଁ ।<ref name="PI2021" /> ଏହା ପାଟିରେ ଦିଆଯାଏ ।<ref name="AHFS2021">{{Cite web|title=Encorafenib Monograph for Professionals |url=https://www.drugs.com/monograph/encorafenib.html |website=Drugs.com |language=en |archive-date=20 July 2021 |archive-url=https://web.archive.org/web/20210720091715/https://www.drugs.com/monograph/encorafenib.html |url-status=live |access-date=15 December 2021}}</ref>


ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଥକ୍କାଣ, ଅଇ, ତରଳ ଝାଡ଼ା, ପେଟ ଯନ୍ତ୍ରଣା, ରାସ ଏବଂ ଗଣ୍ଠି ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।<ref name="PI2021">{{Cite web |title=DailyMed - BRAFTOVI- encorafenib capsule |url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c |url-status=live |archive-url=https://web.archive.org/web/20210421103420/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c |archive-date=21 April 2021 |access-date=15 December 2021 |website=dailymed.nlm.nih.gov}}<cite class="citation web cs1" data-ve-ignore="true">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c "DailyMed - BRAFTOVI- encorafenib capsule"]. </cite></ref> ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ରକ୍ତସ୍ରାବ, [[ୟୁଭିଆଇଟିସ|ୟୁଭିଆଇଟିସ୍]], [[ଲଙ୍ଗ କ୍ୟୁଟି ସିଣ୍ଡ୍ରୋମ]] ଏବଂ ଅନ୍ୟାନ୍ୟ କର୍କଟ ହୋଇପାରେ ।<ref name="PI2021">{{cite web |title=DailyMed - BRAFTOVI- encorafenib capsule |url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c |website=dailymed.nlm.nih.gov |accessdate=15 December 2021 |archive-date=21 April 2021 |archive-url=https://web.archive.org/web/20210421103420/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c |url-status=live }}</ref> ଯେଉଁମାନଙ୍କର ସାମାନ୍ୟ ଯକୃତ ସମସ୍ୟା ଥାଏ, ସେମାନଙ୍କୁ ଏକ ନିମ୍ନ ମାତ୍ରାର ଔଷଧ ଦେବା ଉଚିତ୍ ।<ref name="BNF81">{{Cite book |title=BNF 81: March-September 2021 |date=2021 |publisher=BMJ Group and the Pharmaceutical Press |isbn=978-0857114105 |page=1023}}</ref> ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।<ref name="PI2021">{{cite web |title=DailyMed - BRAFTOVI- encorafenib capsule |url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c |website=dailymed.nlm.nih.gov |accessdate=15 December 2021 |archive-date=21 April 2021 |archive-url=https://web.archive.org/web/20210421103420/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c |url-status=live }}</ref> ଏହା ଏକ କାଇନେଜ ଇନହିବିଟର ଯାହା ବିଆରଏଏଫ (BRAF) ପୁଷ୍ଟିସାରକୁ ଅବରୋଧ କରିଥାଏ ।<ref name="PI2021">{{cite web |title=DailyMed - BRAFTOVI- encorafenib capsule |url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c |website=dailymed.nlm.nih.gov |accessdate=15 December 2021 |archive-date=21 April 2021 |archive-url=https://web.archive.org/web/20210421103420/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c |url-status=live }}</ref> <ref name="EPAR2021">{{Cite web |title=Braftovi |url=https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi |url-status=live |archive-url=https://web.archive.org/web/20210916121142/https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi |archive-date=16 September 2021 |access-date=15 December 2021}}</ref>
ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଥକ୍କାଣ, ଅଇ, ତରଳ ଝାଡ଼ା, ପେଟ ଯନ୍ତ୍ରଣା, ରାସ ଏବଂ ଗଣ୍ଠି ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।<ref name="PI2021" /> ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ରକ୍ତସ୍ରାବ, [[ୟୁଭିଆଇଟିସ|ୟୁଭିଆଇଟିସ୍]], [[ଲଙ୍ଗ କ୍ୟୁଟି ସିଣ୍ଡ୍ରୋମ]] ଏବଂ ଅନ୍ୟାନ୍ୟ କର୍କଟ ହୋଇପାରେ ।<ref name="PI2021" /> ଯେଉଁମାନଙ୍କର ସାମାନ୍ୟ ଯକୃତ ସମସ୍ୟା ଥାଏ, ସେମାନଙ୍କୁ ଏକ ନିମ୍ନ ମାତ୍ରାର ଔଷଧ ଦେବା ଉଚିତ୍ ।<ref name="BNF81">{{Cite book |title=BNF 81: March-September 2021 |date=2021 |publisher=BMJ Group and the Pharmaceutical Press |isbn=978-0857114105 |page=1023}}</ref> ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।<ref name="PI2021" /> ଏହା ଏକ କାଇନେଜ ଇନହିବିଟର ଯାହା ବିଆରଏଏଫ (BRAF) ପୁଷ୍ଟିସାରକୁ ଅବରୋଧ କରିଥାଏ ।<ref name="PI2021" /> <ref name="EPAR2021">{{Cite web |title=Braftovi |url=https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi |url-status=live |archive-url=https://web.archive.org/web/20210916121142/https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi |archive-date=16 September 2021 |access-date=15 December 2021}}</ref>


୨୦୧୮ ମସିହାରେ ଆମେରିକା ଏବଂ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଏନକୋରାଫେନିବକୁ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।<ref name="AHFS2021">{{Cite web|title=Encorafenib Monograph for Professionals |url=https://www.drugs.com/monograph/encorafenib.html |website=Drugs.com |language=en |archive-date=20 July 2021 |archive-url=https://web.archive.org/web/20210720091715/https://www.drugs.com/monograph/encorafenib.html |url-status=live |access-date=15 December 2021}}<cite class="citation web cs1" data-ve-ignore="true">[https://www.drugs.com/monograph/encorafenib.html "Encorafenib Monograph for Professionals"]. ''Drugs.com''. [https://web.archive.org/web/20210720091715/https://www.drugs.com/monograph/encorafenib.html Archived] from the original on 20 July 2021<span class="reference-accessdate">. Retrieved <span class="nowrap">15 December</span> 2021</span>.</cite></ref> <ref name="EPAR2021">{{Cite web |title=Braftovi |url=https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi |url-status=live |archive-url=https://web.archive.org/web/20210916121142/https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi |archive-date=16 September 2021 |access-date=15 December 2021}}<cite class="citation web cs1" data-ve-ignore="true">[https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi "Braftovi"]. </cite></ref> ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୧ରେ ଏହି ଔଷଧର ୪ ସପ୍ତାହ ବ୍ୟବ‌ହାର ପାଇଁ ୫୬୦୦ ମୂଲ୍ୟ ଦେବାକୁ ପଡ଼େ ।<ref name="BNF81">{{Cite book |title=BNF 81: March-September 2021 |date=2021 |publisher=BMJ Group and the Pharmaceutical Press |isbn=978-0857114105 |page=1023}}<cite class="citation book cs1" data-ve-ignore="true">''BNF 81: March-September ''</cite></ref> ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୧୨,୪୦୦ ଡଲାର ଅଟେ ।<ref>{{Cite web |title=Braftovi Prices, Coupons & Patient Assistance Programs |url=https://www.drugs.com/price-guide/braftovi |url-status=live |archive-url=https://web.archive.org/web/20210419015921/https://www.drugs.com/price-guide/braftovi |archive-date=19 April 2021 |access-date=15 December 2021 |website=Drugs.com |language=en}}</ref>
୨୦୧୮ ମସିହାରେ ଆମେରିକା ଏବଂ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଏନକୋରାଫେନିବକୁ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।<ref name="AHFS2021" /> <ref name="EPAR2021" /> ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୧ରେ ଏହି ଔଷଧର ୪ ସପ୍ତାହ ବ୍ୟବ‌ହାର ପାଇଁ ୫୬୦୦ ମୂଲ୍ୟ ଦେବାକୁ ପଡ଼େ ।<ref name="BNF81" /> ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୧୨,୪୦୦ ଡଲାର ଅଟେ ।<ref>{{Cite web |title=Braftovi Prices, Coupons & Patient Assistance Programs |url=https://www.drugs.com/price-guide/braftovi |url-status=live |archive-url=https://web.archive.org/web/20210419015921/https://www.drugs.com/price-guide/braftovi |archive-date=19 April 2021 |access-date=15 December 2021 |website=Drugs.com |language=en}}</ref>


== ଆଧାର ==
== ଆଧାର ==

୦୮:୪୦, ୧୨ ମଇ ୨୦୨୪ ହୋଇଥିବା ରିଭିଜନ

ଏନକୋରାଫେନିବ
Clinical data
Trade namesBraftovi
SynonymsLGX818
AHFS/Drugs.commonograph
MedlinePlusa618040
data
Routes of
administration		By mouth
Legal status
Legal status
Identifiers
  • Methyl [(2S)-1-{[4-(3-{5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl}-1-isopropyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino}-2-propanyl]carbamate
Chemical and physical data
FormulaC22H27ClFN7O4S
Molar mass୫୪୦.୦୧ g·mol−1
3D model (JSmol)
  • C[C@@H](CNc1nccc(n1)c2cn(nc2c3cc(cc(c3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC
  • InChI=1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1
  • Key:CMJCXYNUCSMDBY-ZDUSSCGKSA-N

ଏନକୋରାଫେନିବ (ଇଂରାଜୀ ଭାଷାରେ Encorafenib), ବ୍ରାଫ୍ଟୋଭି ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ମେଲାନୋମା ଏବଂ ବୃହଦନ୍ତ୍ର ମଳାଶୟ କର୍କଟ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ଏକ ଔଷଧ ।[୧] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ବ୍ୟବହୃତ ହୁଏ ଯେତେବେଳେ ଅସ୍ତ୍ରୋପଚାର ଦ୍ୱାରା ବିଆରଏଏଫ ଭି୬୦୦ଇ (BRAF V600E) କିମ୍ବା ଭି୬୦୦କେ (V600K) ମ୍ୟୁଟେସନ୍-ପଜିଟିଭ୍ ରୋଗ ଅପସାରଣ କରାଯାଇପାରିବ ନାହିଁ ।[୧] ଏହା ପାଟିରେ ଦିଆଯାଏ ।[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଥକ୍କାଣ, ଅଇ, ତରଳ ଝାଡ଼ା, ପେଟ ଯନ୍ତ୍ରଣା, ରାସ ଏବଂ ଗଣ୍ଠି ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।[୧] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ରକ୍ତସ୍ରାବ, ୟୁଭିଆଇଟିସ୍, ଲଙ୍ଗ କ୍ୟୁଟି ସିଣ୍ଡ୍ରୋମ ଏବଂ ଅନ୍ୟାନ୍ୟ କର୍କଟ ହୋଇପାରେ ।[୧] ଯେଉଁମାନଙ୍କର ସାମାନ୍ୟ ଯକୃତ ସମସ୍ୟା ଥାଏ, ସେମାନଙ୍କୁ ଏକ ନିମ୍ନ ମାତ୍ରାର ଔଷଧ ଦେବା ଉଚିତ୍ ।[୩] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।[୧] ଏହା ଏକ କାଇନେଜ ଇନହିବିଟର ଯାହା ବିଆରଏଏଫ (BRAF) ପୁଷ୍ଟିସାରକୁ ଅବରୋଧ କରିଥାଏ ।[୧] [୪]

୨୦୧୮ ମସିହାରେ ଆମେରିକା ଏବଂ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଏନକୋରାଫେନିବକୁ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।[୨] [୪] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୧ରେ ଏହି ଔଷଧର ୪ ସପ୍ତାହ ବ୍ୟବ‌ହାର ପାଇଁ ୫୬୦୦ ମୂଲ୍ୟ ଦେବାକୁ ପଡ଼େ ।[୩] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୧୨,୪୦୦ ଡଲାର ଅଟେ ।[୫]

ଆଧାର[ସମ୍ପାଦନା]

  1. ↑ ୧.୦ ୧.୧ ୧.୨ ୧.୩ ୧.୪ ୧.୫ "DailyMed - BRAFTOVI- encorafenib capsule". dailymed.nlm.nih.gov. Archived from the original on 21 April 2021. Retrieved 15 December 2021.
  2. ↑ ୨.୦ ୨.୧ "Encorafenib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 20 July 2021. Retrieved 15 December 2021.
  3. ↑ ୩.୦ ୩.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1023. ISBN 978-0857114105.
  4. ↑ ୪.୦ ୪.୧ "Braftovi". Archived from the original on 16 September 2021. Retrieved 15 December 2021.
  5. ↑ "Braftovi Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 19 April 2021. Retrieved 15 December 2021.
"https://or.wikipedia.org/w/index.php?title=ଏନକୋରାଫେନିବ&oldid=539812"ରୁ ଅଣାଯାଇଅଛି